These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 12574694)

  • 1. Advances in the treatment of secondary pulmonary hypertension.
    Maloney JP
    Curr Opin Pulm Med; 2003 Mar; 9(2):139-43. PubMed ID: 12574694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pulmonary arterial hypertension and systemic sclerosis].
    Launay D; Humbert M; Hachulla E
    Presse Med; 2006 Dec; 35(12 Pt 2):1929-37. PubMed ID: 17159719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosentan for the treatment of portopulmonary hypertension.
    Tempe DK; Datt V; Datta D
    Ann Card Anaesth; 2008; 11(2):139-40; author reply 140. PubMed ID: 18603763
    [No Abstract]   [Full Text] [Related]  

  • 5. Pulmonary arterial hypertension: combination therapy in the modern management era.
    Sitbon O
    Eur Respir Rev; 2010 Dec; 19(118):348-9. PubMed ID: 21119195
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination drug therapy in the management of pulmonary arterial hypertension.
    Kayser SR
    Prog Cardiovasc Nurs; 2005; 20(4):177-82. PubMed ID: 16276142
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
    Steele P; Strange G; Wlodarczyk J; Dalton B; Stewart S; Gabbay E; Keogh A
    BMC Cardiovasc Disord; 2010 Feb; 10():9. PubMed ID: 20170553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?
    Brancaccio G; Toscano A; Bevilacqua M; Di Chiara L; Parisi F
    Pediatr Transplant; 2007 Feb; 11(1):110-2. PubMed ID: 17239133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bosentan and chronic thromboembolic pulmonary hypertension].
    Tomás C; Callejas-Rubio JL; Ríos-Fernández R; Ortego-Centeno N
    Med Clin (Barc); 2007 Nov; 129(16):639. PubMed ID: 18001681
    [No Abstract]   [Full Text] [Related]  

  • 12. [The combined use of sildenafil with epoprostenol in a patient with primary pulmonary hypertension].
    Kayikçioğlu M; Can LH; Payzin S; Kültürsay H; Soydan I
    Anadolu Kardiyol Derg; 2002 Sep; 2(3):262-4. PubMed ID: 12223337
    [No Abstract]   [Full Text] [Related]  

  • 13. Portopulmonary hypertension.
    Nayak RP; Li D; Matuschak GM
    Curr Gastroenterol Rep; 2009 Feb; 11(1):56-63. PubMed ID: 19166660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies.
    Krishnan U; Krishnan S; Gewitz M
    Pediatr Cardiol; 2008 Nov; 29(6):1082-6. PubMed ID: 18594787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evidence-based approach to the management of pulmonary arterial hypertension.
    Archer SL; Michelakis ED
    Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and meta-analysis of pulmonary hypertension specific therapy for exercise capacity in chronic obstructive pulmonary disease.
    Park J; Song JH; Park DA; Lee JS; Lee SD; Oh YM
    J Korean Med Sci; 2013 Aug; 28(8):1200-6. PubMed ID: 23960448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome].
    Raposo-Sonnenfeld I; Otero-González I; Blanco-Aparicio M; Ferrer-Barba A; Medrano-López C
    Rev Esp Cardiol; 2007 Apr; 60(4):366-72. PubMed ID: 17521545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sildenafil as a substitute for subcutaneous prostacyclin in pulmonary hypertension].
    Cea-Calvo L; Escribano Subías P; Tello de Menesses R; Gómez Sánchez MA; Delgado Jiménez JF; Sáenz de la Calzada C
    Arch Bronconeumol; 2003 Oct; 39(10):476-7. PubMed ID: 14533998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.